Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Recipharm has announced an agreement whereby it will acquire Hospira subsidiary, Wasserburger Arzneimittelwerk, located in Wasserburg, Southern Germany, on 31 January, 2010. The transaction is likely to enhance Recipharm’s capabilities, enabling it to offer efficient, large-scale lyophilisation services alongside its existing smaller scale operation in Basle.
Subscribe to our email newsletter
Wasserburger is a contract manufacturing organisation specialised in the aseptic filling and lyophilsation of pharmaceuticals into ampoules and vials, on behalf of a range of customers.
The acquisition of Wasserburger forms a part of Recipharm’s strategic goal to become a leading Contract Development and Manufacturing Organisations (CDMO), by offering a ‘one stop shop’ for the development and manufacturing of traditional pharma and biopharmaceuticals.
Recipharm has confirmed that it will continue to offer the full spectrum of Wasserburger’s current services and intends to retain all of the employees.
Thomas Eldered, CEO of Recipharm, said: “We are extremely happy to be acquiring such an excellent facility and skilled employees in the strategically important market of Germany. Combining this technology with our existing capabilities will I believe enable us to maximise our growth potential and put us in a very strong position for the future. We are also pleased to be extending our customer base and we look forward to being able to offer a wider range of capabilities to them”
Terrence Kearney, chief operating officer of Hospira, said: “Divesting Wasserburg supports Hospira’s Project Fuel optimization initiative and strategic efforts to drive efficiency across our global manufacturing footprint. This agreement reduces manufacturing redundancies and complexity, while freeing up resources to invest in new manufacturing technology. Hospira’s recent acquisition in Europe and planned purchase in India represent the types of manufacturing investments that will drive sustainable growth in our core specialty injectable pharmaceutical and related One 2 One contracting manufacturing business.”